Swan NeuroTech

Executive Summary

Swan NeuroTech, a San Diego-based biotechnology startup founded in 2019, is pioneering biomaterial-based solutions for peripheral nerve repair. The company’s core technology comprises biodegradable drug-delivery implants designed to enhance nerve regeneration and improve functional recovery following traumatic injuries. Peripheral nerve injuries affect millions globally, often leading to chronic pain, loss of sensation, or paralysis, yet current treatments like autografts have limited success. Swan’s novel implants combine structural support with controlled release of neurotrophic factors, aiming to provide a more effective, off-the-shelf therapy. The company is in the preclinical phase, having demonstrated promising results in animal models, and is working toward regulatory filings to advance into human trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Data Presentation at Major Neuroscience Conference80% success
• Q2 2026Series A Funding Round Completion70% success
• Q1 2027FDA Pre-IND Meeting Submission60% success